There will be one Principal Investigator overseeing up to two sub-PIs at up to two independent testing sites in this pilot study, as follows:
Testing Site: At the testing site location(s), the sub-PI(s) will conduct the study qualification evaluation and record the study outcome measures.
Clinical Site: The clinical site location will house the Resonator™ device and is where the study PI will execute the procedure administrations with the Resonator™. The clinical site location will be the same for all testing sites.
The testing and clinical site locations will be close enough to each other so that a qualifying subject who is comfortably able to travel to one of the locations will also be able to comfortably travel to the other. For any single scheduled study visit, subjects will only need to attend one of the two study site locations. During the informed consent review process, subjects will be informed of the two study site locations and when they will need to attend each.
The Resonator™ device is an Investigational Device limited by Federal (or United States)
law to investigational use. The Resonator™ device is not for sale, nor is the
Magneceutical®
Therapy generally available outside of Investigational Review Board (IRB) approved clinical studies.